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potential tumor suppressor, expression of which is downregu-
lated in various human tumor types. Additionally, Pdcd4 is able
to inhibit the neoplastic transformation in the JB6 mouse model.
Pdcd4 has been shown to inhibit translation of diverse regula-
tory factors important for neoplastic transformation. Moreover,
it was shown that AKT phosphorylates Pdcd4, causing nuclear
translocation and inactivation of the latter. This suggests that
Pdcd4 activity is dependent on its cellular localisation. Up to
now, Pdcd4 protein expression and cellular localisation has not
been analysed in a large series of patients with colorectal cancer
(CRC).
Methods: We investigated the expression pattern and localisa-
tion of Pdcd4 tumor suppressor protein in resected tumor and
corresponding normal tissue in a series of 41 CRC patients (32
R0-resected) who did not receive neoadjuvant treatment, by Wes-
tern blotting (WB) and immunhistochemistry (IHC). A separate
semiquantitative score for ICH staining of the cytoplasm and
nuclei was established. Preliminary analysis of Pdcd4 expression
and localisation was correlated with patient’s clinical tumor stage
(UICC) and with recurrence-free survival.
Results: In WB high overall Pdcd4 amounts were detected in nor-
mal tissue in comparison to the tumor samples where the signal
was significantly decreased (p = 0.025, Wilcoxon). IHC analysis
revealed strong nuclear presence of Pdcd4 in the apical cryptal
epithelium of normal tissue, as opposed to the complete loss of
nuclear expression in tumor tissue (p = 0.001, Wilcoxon). In nor-
mal tissue, loss of Pdcd4 nuclear expression/increase of cytoplas-
mic Pdcd4-staining was significantly associated with advanced
UICC stages (p = 0.027, v2). Preliminary Kaplan–Meier-analysis
(median recurrence-free survival time: 38 months, range: 1–74
months) showed a trend for loss of Pdcd4 expression in the nuclei
of the normal tissue to be associated with poor recurrence-free
survival (p = 0.09, Breslow log rank).
Conclusion: This is the first clinical study that demonstrates a
potential relevance of Pdcd4 expression and localisation in
resected colorectal tumors and corresponding normal tissue, for
tumor diagnosis and progression. Further analysis of colorectal
adenomas will be performed to study the role of Pdcd4 localisa-
tion as a potential clinical marker for carcinogenesis in CRC.
doi:10.1016/j.ejcsup.2006.04.065
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University Hospital, Cre´teil, France.Background: Proteinases activated receptors (PARs) are impor-
tant members of the G protein-coupled receptors family. The
proteolytic cleavage of their extracellular domain by serine pro-
teases such as trypsin or thrombin, generates an autoactivating
tethered-ligand. Thus, the corresponding activated G proteins
trigger a cascade of downstream events leading to diverse cellu-
lar outcomes such as calcium signalling, cell adhesion, cell
migration and mitogenesis. The role of proteases in promoting
invasion of cancer cells and tumorigenesis have prompted us
to study the expression level and localisation of the four known
members of the PARs family and explore their role in cell
proliferation.
Methods: First, by using quantitative RT-PCR, we have quanti-
fied: (i) the expression of each PAR in colon and prostate cancer
cell lines, (ii) the PARs expression in 40 patients samples (colon
or prostate normal tissue and cancer). Second, we have studied
PARs tissue localisation in colon and prostate, by using immuno-
histochemistry staining on TMA samples. Finally, we investigated
the role of the four members of PAR family (PAR1-4) in cell prolif-
eration by stimulating cell lines in different conditions (various
thrombin concentrations).
Results: Our results show that the expression profile of the PARs
is different for each PAR and depend mostly of the cell lines char-
acterisation (origin and stage). However, we demonstrate a con-
stant overexpression of two PARs in every tested cell line, that
was also found in tumor samples.
Immunohistochemichal analysis shows PAR1 endothelial
expression which was stronger in malignant tissues (prostate
and colon samples), and weaker (prostate) or absent (colon) in
normal tissues.
Conclusion: These results confirm the importance of PARs in
cancer, whose expression pattern is likely to influence cancer cell
behaviour in tumors.
doi:10.1016/j.ejcsup.2006.04.066
P7. COMPLETE COMPILATION OF MATRIX
METALLO-PROTEINASE EXPRESSION IN HUMAN
MALIGNANT GLIOMAS
Jelena Stojic, Carsten Hagemann, Siglinde Ku¨hnel, Stefanie
Gerngras, Klaus Roosen, Giles Hamilton Vince. Neurochirurgische
Universita¨tsklinik, Tumorbiologisches Labor, Josef-Schneider-Strasse 11,
D-97080 Wu¨rzburg, Germany.
Background: Glioblastomas are the most common malignant
brain tumors in adults characterized by very aggressive local growth
and invasiveness. Tumor invasion into surrounding brain tissue is
facilitated by increased expression and activity of matrix metallo-
proteinases (MMPs), which may be marker for tumor aggressive-
ness. However, for several of the 23 human MMPs there are no or
only very limited literature data available concerning expression
by glioblastomas. Therefore, we screened an extensive panel of 15
low-grade astrocytomas and 15 glioblastomas in order to fill the
gaps in our knowledge about MMP expression by these tumors.
Methods: Expression of MMPs was analysed by semiquantitative
RT-PCR and immunostaining. Total RNA was used as template for
RT-PCR. Immunostaining was performed on cryosections.
